AstraZeneca (AZN) Market Capitalization, Earnings, Price, Holders
Symbol: AZN Rank: #36 Price: $74.285(-0.40889%)

Market Cap: $230.2B($-941.5M) Industry: Drug Manufacturers General Sector: Healthcare Country: United Kingdom Insiders: 0.046% Institutions: 17.724%
AstraZeneca PLC Technicals

52 Week High: $74.29

52 Week Low: $51.9

50 Day MA: $67.92

200 Day MA: $64.24

52 Week Trading Range


Low: $51.9

High: $74.29

Daily Trading Range


Low: $74.125

High: $74.6162

Market capitalization history for AstraZeneca (AZN) in USD

As of December 2023, AstraZeneca (AZN) has a market cap of $230.2 billion. Our data points out that AZN is ranked #36 in the world. A company's market capitalization is the present value of all of its outstanding shares, and it is commonly used to give a sense of how much the stock of a company would be worth at today's exchange rates. AZN's market cap is -0.408892% down from the last trading day.

AZN Statistics

Market Cap
Revenue TTM
Gross Profit TTM
Operating Margin TTM
Shares Outstanding
Shares Float
Trading Volume
P/E Ratio
PEG Ratio
Revenue Per Share
Dividend Per Share
Dividend Yield
Quote Type
Leaf logo
CDP Climate Change Score (AZN)

Latest News

AstraZeneca (AZN) Shares Stats
AstraZeneca (AZN) Valuation
Trailing P/E $61.3113
Forward P/E $18.4162
Price Sales TTM $4.6505
Price Book MRQ $6.2133
Enterprise Value $241,103,609,999
Enterprise Value Revenue $5.3395
Enterprise Value Ebitda $28.1105
AstraZeneca PLC Details

Address: 1 Francis Crick Avenue

City: Cambridge

Zip: CB2 0AA

Phone: 44 20 3749 5000


IPO Date: 1993-05-12

CEO: Pascal Soriot D.V.M., M.B.A.

Employees: 83,100

What is AZN about?

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.